Pediatrix Medical Group 株価情報 (NYSE: MD)

Pediatrix Medical Group (NYSE:MD) 株価情報

Pediatrix Medical Group

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group Inc

Moeda Loyalty Points

Spectral AI Inc

MAEDA KOSEN CO LTD by MAEDA KOSEN CO LTD.

MDA Space Ltd

DAVI LUXURY BRAND GRP INC by Davi Luxury Brand Group, Inc.

Davi Luxury Brand Group Inc

Media Way Corp

MongoDB Inc

MEDLAB CLINICAL LTD by Medlab Clinical Ltd.

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings LLC

TrivarX Ltd

MEDIBANK PRIVATE UNSP/ADR by MEDIBANK PRIVATE LTD

Medibank Pvt Ltd

MEDIBANK PRIVATE LTD by MEDIBANK PRIVATE LTD

M.D.C. Holdings, Inc. Com.

MEDICAL CARE TECHS INC by Medical Care Technologies Inc.

Medical Care Technologies Inc

Chapters Group AG

Medincell SA

MEDICAN ENTERPRISES INC by Medican Enterprises Inc

Medican Enterprises Inc

VictoryShares THB Mid Cap ETF

Medicus Pharma Ltd

Medicus Pharma Ltd. - Warrant

Media Do Co Ltd

MDM GROUP INC by MDM Group, Inc.

MERIDIAN ENERGY LTD by Meridian Energy LTD

Meridian Energy Ltd

MANDATUM OYJ U/ADR by MANDATUM OYJ

MEDICAL DEV INTL LTD ORD by Medical Developments International Ltd.

Medical Developments International Ltd

Media 100 Inc

ARNOLDO MONDADORI E U/ADR by Arnoldo Mondadori Editore Spa

Arnoldo Mondadori Editore SpA

First Trust Indxx Medical Devices ETF

MELCO INTL DEVEL by Melco International Development Limited

Melco International Development Ltd

MELCO INTL DEV LTD UNSADR by Melco International Development Limited

MADISON TECHNOLOGIES INC by Madison Technologies Inc.

Madison Technologies Inc

MediaG3 Inc

Medigene AG Namen-Akt. nach Kapitalherabsetzung

Medigene AG

MELODIOL GLBL HLTH 2028 by MELODIOL GLOBAL HEALTH LTD

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Medgroup Inc

MENDELL HELIUM PLC by MENDELL HELIUM PLC

Mediaco Holding Inc. - Class A Common Stock

MediaCo Holding Inc

Mediobanca SpA

MEDIOBANCA SPA UNSP/ADR by MedioBanca SpA

MIDLAND IC&I LTD by Midland IC&I Ltd

Modec Inc

MedGen Inc

MEDITE CANCER DIAGNOSTICS by Medite Cancer Diagnostics, Inc.

Medite Cancer Diagnostics Inc

Multi-Asset Diversified Income Index Fund

MR D I Y GROUP M BERHAD by MR D I Y GROUP M BERHAD

Mr D.I.Y. Group (M) Bhd

Mdechem Inc

MEDICAL INTL TECH INC by Medical International Technology, Inc.

Medical International Technology Inc

MEDLEY MANAGEMENT A by Medley Management, Inc.

Medley Management Inc

EA Series Trust Morgan Dempsey Large Cap Value ETF

MEDLIVE TECH CO LTD U/ADR by MEDLIVE TECHNOLOGY CO LTD

MEDLEY Inc

Mondelez International, Inc. - Class A Common Stock

Mondelez International Inc

MIDAS MINERALS LTD by MIDAS MINERALS LTD.

MEDINAH MINERALS INC by Medinah Minerals, Inc.

Medinah Minerals Inc

MDM Permian Inc

Medmix AG

MEDICENNA THERAPEUTICS CORP COM

MEDICENNA THERA CORP by Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp

Medinotec Inc

MCDONALDS HLDGS JAPAN ORD by McDonalds Hldgs Co Japan Ltd.

McDonald's Holdings Co (Japan) Ltd

MIDNIGHT SUN MINING CORP by Midnight Sun Mining Corp

Midnight Sun Mining Corp

MAIDEN LANE JEWELRY LTD by Maiden Lane Jewelry, Ltd.

Mednow Inc

Mandom Corp

MAISONS DU MONDE SA by Maisons Du Monde SA

Maisons du Monde France SA

MADISON PAC PPTYS B ORD by Madison Pacific Properties Inc.

Madison Pacific Properties Inc

MedPeer Inc

Northern Lights Fund Trust IV Monarch Dividend Plus Index ETF

MD ENTERTAINMENT TBK PT by MD ENTERTAINMENT TBK PT

PT MD Entertainment Tbk

Medra Corp

Mandarake Inc

mDR Ltd

MODERN MOBILITY AIDS INC by Modern Mobility Aids, Inc.

Modern Mobility Aids Inc

Modern Plant Based Foods Inc

MODERN PLT BASE FOODS INC by Modern Plant Based Foods Inc.

Medalist Diversified REIT, Inc. - Common Stock

Medalist Diversified REIT Inc

Medalist Diversified REIT Inc PRF PERPETUAL USD 25 - Series A

MEDARTIS HOLDING AG by MEDARTIS HOLDING AG

Medartis Holding AG

Veradigm Inc

MATRIX DENTURE SYS INTL by Matrix Denture Systems International, Inc.

Matrix Denture Systems International Inc

TEN SIXTY FOUR LTD by TEN SIXTY FOUR LTD.

Ten Sixty Four Ltd

MINSUD RESOURCES ORD by Minsud Resources Corp

Minsud Resources Corp

Ultimus Managers Trust Westwood Salient Enhanced Midstream Income ETF

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.38, a high estimate of $18.50, and a low estimate of $15.00. Marking an increase of 9.79%, the current average surpasses the previous average price target of $15.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175259_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pediatrix Medical Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pediatrix Medical Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pediatrix Medical Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Pediatrix Medical Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pediatrix Medical Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pediatrix Medical Group: A Closer Look</h2>
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.
<h3>Key Indicators: Pediatrix Medical Group's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pediatrix Medical Group's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 0.9%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pediatrix Medical Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.8%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Pediatrix Medical Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.7%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pediatrix Medical Group's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pediatrix Medical Group's debt-to-equity ratio is below the industry average at 0.93, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Beyond The Numbers: 4 Analysts Discuss Pediatrix Medical Group Stock

UBS analyst A.J. Rice maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Neutral and raises the price target from $16.5 to $18.5.

News

Price Target

UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $18.5

Truist Securities analyst David Macdonald maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Hold and raises the price target from $15 to $18.

Truist Securities Maintains Hold on Pediatrix Medical Group, Raises Price Target to $18

As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Pulmonx Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>)</h3>
<ul>
<li>On Feb. 19, Pulmonx reported better-than-expected quarterly financial results and issued FY25 sales guidance above estimates. &#8220;Our record quarterly and full year results underscore the continued success of our focused strategy and execution in further expanding our account base, optimizing patient workflows, and raising awareness among both patients and referring physicians,&#8221; said Steve Williamson, President &amp; Chief Executive Officer. The company's stock gained around 44% over the past month and has a <a href="https://www.benzinga.com/quote/LUNG">52-week high of $14.52</a>.</li>
<li>RSI Value: 75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LUNG Price Action: Shares of Pulmonx gained 44.3% to trade at $8.93 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Pediatrix Medical Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>)</h3>
<ul>
<li>On Feb. 20, Pediatrix Medical Group reported better-than-expected quarterly financial results. &#8220;Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions,&#8221; said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. The company's stock gained around 21% over the past month and <a href="https://www.benzinga.com/quote/MD">has a 52-week high</a> of $17.67.</li>
<li>RSI Value: 73.3</li>
<li>MD Price Action: Shares of Pediatrix Medical gained 20.5% to trade at $16.91 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">SpringWorks Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)</h3>
<ul>
<li>On Feb. 20, SpringWorks Therapeutics posted FY 2024 GAAP loss of $3.48 per share on sales of $191.59 million. &#8220;We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are still in the early stages of realizing the full potential of our opportunity to serve the desmoid tumor community. With the recent FDA approval of GOMEKLI for adults and children with NF1-PN, we believe we are ready to deliver another strong launch and are delighted that the broad label enables us to help patients throughout their treatment journey,&#8221; said Saqib Islam, Chief Executive Officer of SpringWorks. The company's stock gained around 65% over the past month and has a<a href="https://www.benzinga.com/quote/SWTX"> 52-week high</a> of $62.00.</li>
<li>RSI Value: 75.1</li>
<li>SWTX Price Action: Shares of SpringWorks Therapeutics gained 7.7% to trade at $60.02 on Thursday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai">Alibaba Q3 Earnings: Revenue And EPS Beat, Eyes Global E-Commerce Profitability In FY25, Increase Investments In AI</a></li>
</ul>

Short Ideas

Markets

Trading Ideas

LUNG

SWTX

Top 3 Health Care Stocks You May Want To Dump In February

U.S. stocks were lower, with the Dow Jones falling over 1% on Thursday.
Shares of Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) rose sharply during Thursday's session after the company reported third-quarter financial results and beat its adjusted EPADS and <a href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai">revenue estimates</a>.
The Jack Ma co-founded e-commerce giant reported fiscal third-quarter 2024 revenue growth of 8% year-on-year to $38.38 billion, beating the analyst consensus estimate of $38.19 billion. Adjusted earnings per ADS of $2.93 beat the analyst consensus estimate of $2.66. Adjusted net income rose 7% Y/Y to $7 billion.
Alibaba Group shares jumped 9.5% to $137.77 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) shares jumped 42.5% to $8.01 after the company reported fourth-quarter EPS and revenue above estimates.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 26.6% to $27.19 after the company reported better-than-expected quarterly financial results.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 20.5% to $17.01 after the company reported better-than-expected quarterly financial results.</li>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) gained 13.8% to $143.11 after the company determined that allegations from recent short seller reports were without merit and said it expects to file its 10-K on time.</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) gained 13.4% to $69.36 after the company reported better-than-expected quarterly financial results.</li>
<li>Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) rose 12.7% to $125.32 after the company reported quarterly EPS and revenue above estimates.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) gained 10.7% to $7.21 after the company reported better-than-expected quarterly sales.</li>
<li>Manulife Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFC#NYSE">MFC</a>) rose 7.3% to $31.96 after the company announced a dividend raise and a reduction in its shares outstanding through a normal course issuer bid.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) gained 6.2% to $28.13. The company is preparing to launch its next-generation technologies aimed at improving optical connections within data centers and AI clusters.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43851159/how-to-earn-500-a-month-from-newmont-stock-ahead-q4-earnings">How To Earn $500 A Month From Newmont Stock Ahead Of Q4 Earnings</a></li>
</ul>

Intraday Update

Movers

BABA

FTAI

SHAK

Alibaba, Hasbro, Shake Shack, Bausch Health And Other Big Stocks Moving Higher On Thursday

On Thursday, Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) reported fourth-quarter sales of $502.36 million. That&#8217;s up from $496.4 million a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $486.21 million</a>.
The increase reflected growth in same-unit revenue of 8.7%, partially offset by the impact of the non-same-unit activity, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43842307/pediatrix-medical-group-reports-fourth-quarter-results" rel="noreferrer noopener">primarily practice dispositions</a>.
The physician services provider reported adjusted EPS of 51 cents. That&#8217;s up from 32 cents a year ago, beating the consensus of 37 cents.
&#8220;Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions,&#8221; said Mark Ordan, Chief Executive Officer of Pediatrix Medical.
Same-unit revenue from net reimbursement-related factors increased by 5.9% for the 2024 fourth quarter, reflecting an improved payor mix and modest improvements in hospital contract administrative fees.
The percentage of services reimbursed by commercial and other non-government payors increased by approximately 200 basis points compared to the prior year period.
Same-unit revenue attributable to patient volume increased by 2.8%.
Guidance: On a preliminary basis, Pediatrix anticipates its 2025 Adjusted EBITDA of approximately between $215 million to $235 million.
William Blair writes, &#8220;While the midpoint of the 2025 adjusted EBITDA guidance range anticipates barely any growth this year, we believe this is likely a conservative estimate; however, given the magnitude of the beat in 2024, the majority of the planned asset divestitures could have been already largely realized at this point.&#8221;
Analyst Ryan Daniels sees Pediatrix as a strong healthcare services company with a good balance of risk and reward for long-term investors. Management&#8217;s focus on improving operations, optimizing revenue cycle management, and cutting costs should boost performance. With shares trading at about 7.5 times 2025 EBITDA target, William Blair <a target="_blank" href="https://www.benzinga.com/quote/MD/analyst-ratings" rel="noreferrer noopener">maintains Outperform rating</a>.
Price Action: Pediatrix stock is up 24% at $17.50 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43849658/why-is-biomarin-stock-trading-higher-on-thursday" target="_blank" rel="noreferrer noopener">Why Is BioMarin Stock Trading Higher On Thursday?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

Health Care

General

Pediatrix Q4 Beats Estimates As Operational Improvements Drive Performance

WIIM

Pediatrix Medical Group shares are trading higher after the company reported better-than-expected Q4 financial results.

Pediatrix Medical shares are trading higher after the company reported better-than-expected Q4 financial results.

Pediatrix Medical Anticipates 2025 Adjusted EBITDA Of $215M-$235M

Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.37 by 37.84 percent. This is a 59.38 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $502.36 million which beat the analyst consensus estimate of $486.21 million by 3.32 percent. This is a 1.19 percent increase over sales of $496.44 million the same period last year.

Comments

Pediatrix Medical Group

ニュース

パートナーシップ

ベンジンガ・グローバル